1. Neurological Immunotoxicity from Cancer Treatment.
- Author
-
Wesley SF, Haggiagi A, Thakur KT, and De Jager PL
- Subjects
- Biomarkers, Pharmacological analysis, Biomarkers, Tumor analysis, CTLA-4 Antigen antagonists & inhibitors, Encephalitis chemically induced, Humans, Immune Checkpoint Inhibitors therapeutic use, Immunotherapy, Adoptive methods, Meningitis, Aseptic chemically induced, Meningitis, Aseptic immunology, Neoplasms immunology, Paraneoplastic Syndromes chemically induced, Receptors, Chimeric Antigen therapeutic use, T-Lymphocytes drug effects, T-Lymphocytes immunology, Immune Checkpoint Inhibitors adverse effects, Immunotherapy adverse effects, Immunotherapy, Adoptive adverse effects, Neoplasms therapy
- Abstract
The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In particular, this review details the neurological irAEs from immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell immunotherapies. The recognition and treatment of neurological irAEs has variable success, depending on the severity and nature of the neurological involvement. Understanding the involved mechanisms, predicting those at higher risk for irAEs, and establishing safety parameters for resuming cancer immunotherapies after irAEs are all important fields of ongoing research.
- Published
- 2021
- Full Text
- View/download PDF